ANXIETY AND DEPRESSION IN TUNISIAN PATIENTS WITH PARKINSON’S DISEASE

INTRODUCTION: Anxiodepressive disorders in Parkinson’s disease (PD) are quite frequent and considered as non-motor signs of the disease. Few studies have studied the link between these entities. OBJECTIVES: The objective of this study is to determinate the prevalence of anxiety and depression in patients with PD, and factors associated with them METHODS: A descriptive and analytical cross-sectional study collected from patients followed at the neurology consultation of Habib Bourguiba’s university Hospital in Sfax, Tunisia. We used: a sociodemographic, clinical and therapeutic data sheet. Hospital Anxiety and Depression Scale(HADS): to study anxiety and depression. A score ≥10 means a certain anxiety or depression. RESULTS: We have involved 47 patients. The average age was 61.47 years with a sex ratio (M/W)=1,47. Amantadine was received by 12.77% of patients, anticholinergics by 14.9% of patients and 87.24% of patients were treated with Levodopa. HADS: the average scale of Depression was8.62 ± 4.54 and the median scaleanxiety was 7 [1-18]. Depression and anxiety were presentin 38.29% and 27.68% of cases, respectively. Depression was significantly correlated with Amantadine intake (P=0.036) and Levodopa dose (P=0.016). Anxiety was significantly associated with anticholinergic intake(P=0.011).Both depression and anxiety were notstatistically correlated to the presence ofmotor complications of dopa therapy (P= 0.44 and 0.7 respectively) CONCLUSIONS: The therapeutic management of patients with PD influences the occurrence of anxiety and depression, which proves the importance of early detection of these disordersto ensure better support DISCLOSURE OF INTEREST: None Declared